Radiotheranostics refers to dual diagnostic–therapeutic capacity that allows for precision medicine at an unprecedented level, reducing collateral toxicity and improving patient outcomes ([1][1]). In ...

In recent years, several radiotracers targeting the prostate-specific membrane antigen (PSMA) have been introduced. Some of them have had a high clinical impact on the treatment of patients with ...

The results are presented as median and interquartile range (IQR) for continuous variables and as number and percentage for categoric variables. Kaplan–Meier analysis was used to estimate overall ...

Good-manufacturing-practice–grade precursor DOTA-Siglec-9 was obtained from ABX Advanced Biomedical Compounds GmbH. All other reagents were purchased from commercial suppliers and were either ...

Prostate cancer is the most common cancer diagnosis in men in the United States and a leading cause of cancer-related morbidity and mortality (1). It can exist along a wide spectrum of aggressiveness ...

SPECT is used to quantitatively and visually assess the distribution of radioactive biologic markers (tracers) in vivo in order to, for example, study animal models of disease and test new ...

High expression of prostate-specific membrane antigen (PSMA) is not limited to prostate cancer but can be found in other tumor entities, such as hepatocellular carcinoma (HCC), and could possibly be ...

Journal of Nuclear Medicine November 2025, jnumed.125.270703; DOI: https://doi.org/10.2967/jnumed.125.270703 ...

The cell cycle is a progression of 4 distinct phases (G1, S, G2, and M), with various cycle proteins being essential in regulating this process. We aimed to develop a radiolabeled cyclin-dependent ...

Pharmacokinetics of radiopharmaceuticals (e.g., radioimmunotherapy agents) are assumed to follow first-order kinetics and are, therefore, approximated by the sum of discrete rates (1–3). However, the ...

Neuroendocrine tumors (NETs) frequently form distant metastases and require systemic treatment (1). An established treatment option in advanced NETs is peptide receptor radionuclide therapy (PRRT) ...

TO THE EDITOR: Peptide receptor radionuclide therapy (PRRT) is highly effective in neuroendocrine tumors (NETs). In the NETTER-1 trial, progression-free survival at month 20 in patients with advanced ...